Xilio Therapeutics, Inc.
XLOHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. Valued at $57.2M, XLO is a micro-cap name in its sector. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Market Cap
$57.2M
Beta
-0.12
P/E (TTM)
—
P/E (Fwd)
-15.00
EPS (TTM)
$-2.32
EPS (Fwd)
$-0.58
ROE
-75.2%
ROA
-19.8%
Cash
$150.3M
Total Debt
$6.6M
Free CF
-$23.0M
52W Change
-11.2%
Annual Financials
Cash vs Debt
Where XLO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, XLO finished 6.61% above its 150-day moving average ($8.47) and 0.66% below its 200-day moving average ($9.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XLO overbought or oversold?
At the July 15, 2026 close, XLO's RSI(14) was 52.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $150.3M in cash comfortably exceeding the $6.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$23.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -75.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Xilio Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, XLO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XLO.